IDEXX Laboratories (IDXX) Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IDXX shares.
View IDXX analyst ratings or view top-rated stocks.

6 equities research analysts have issued 12 month target prices for IDEXX Laboratories' stock. Their IDXX share price forecasts range from $500.00 to $610.00. On average, they expect the company's stock price to reach $571.67 in the next year. This suggests a possible upside of 30.7% from the stock's current price.
View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts.

IDEXX Laboratories' stock was trading at $407.96 at the beginning of 2023. Since then, IDXX stock has increased by 7.2% and is now trading at $437.27.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our IDXX earnings forecast.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings data on Tuesday, August, 1st. The company reported $2.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.24. The business had revenue of $943.63 million for the quarter, compared to analysts' expectations of $927.84 million. IDEXX Laboratories had a trailing twelve-month return on equity of 104.84% and a net margin of 22.52%.

ETFs with the largest weight of IDEXX Laboratories (NASDAQ:IDXX) stock in their portfolio include ProShares Pet Care ETF (PAWZ), Sterling Capital Focus Equity ETF (LCG), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA), First Trust Water ETF (FIW), iShares U.S. Medical Devices ETF (IHI), Neuberger Berman Disrupters ETF (NBDS) and Putnam Sustainable Future ETF (PFUT).

IDEXX Laboratories issued an update on its FY 2023 earnings guidance on Tuesday, August, 1st. The company provided earnings per share (EPS) guidance of $9.64-$9.90 for the period, compared to the consensus earnings per share estimate of $9.69. The company issued revenue guidance of $3.66 billion-$3.71 billion, compared to the consensus revenue estimate of $3.67 billion.

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IDXX stock can currently be purchased for approximately $437.27.

IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $36.29 billion and generates $3.51 billion in revenue each year. The company earns $679.09 million in net income (profit) each year or $9.42 on an earnings per share basis.

The company employs 10,780 workers across the globe.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.